SY2-4Development of Targeted Therapy for Advanced Non-Small Cell Lung Cancer With Rare Driver Oncogenes as RET or MET

Annals of Oncology - United Kingdom
doi 10.1093/annonc/mdy363
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Targeted Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2005English

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy for Non-Small Cell Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2019English

A Decade of Targeted Therapy for Non-Small Cell Lung Cancer

2017English

Salvage Surgery for Advanced Non-Small Cell Lung Cancer After Targeted Therapy: A Case Series

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Ex on 14 Mutant Non-Small Cell Lung Cancer

Clinical Cancer Research
Cancer ResearchOncology
2018English

Anti-Pd-1 Therapy Plus Chemotherapy and/or Bevacizumab as Second Line or Later Treatment for Patients With Advanced Non-Small Cell Lung Cancer

Journal of Cancer
Oncology
2020English

Radiotherapy With or Without Concomitant Chemotherapy as Pre- Or Postoperative Therapy in Non-Small Cell Lung Cancer

Journal of Cancer Science & Therapy
2012English

Shifting the Paradigm for Maintenance Therapy in Advanced Non-Small-Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2010English

Are VEGFR-TKIs Effective or Safe for Patients With Advanced Non-Small Cell Lung Cancer?

Oncotarget
Oncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy